Angelo Labate
Full Professor of Neurology
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Angelo Labate is a Full Professor of Neurology at the University of Messina in Italy. His research focuses on various aspects of epilepsy, including clinical features, treatment efficacy, and neuroimaging. Recent articles by Professor Labate explore topics such as the response to uncertainties in epilepsy care, the introduction of new anti-seizure medications, and the genetic underpinnings of familial epilepsy. He actively contributes to the understanding of both common and complex epilepsy conditions through innovative clinical studies and collaborative research.
Articles (17)
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Objective Epilepsy with generalized tonic–clonic seizures alone (GTCA) is a common but poorly characterized idiopathic generalized epilepsy (IGE) syndrome. Hence, we investigated electroclinical features, seizure outcome, and antiseizure medication (ASM) withdrawal in a large cohort of GTCA patients. Methods In this multicenter retrospective study, GTCA patients defined according to the diagnostic criteria of the International League Against Epilepsy (2022) were included. We investigated prognostic patterns, drug resistance at the last visit, and ASM withdrawal, along with their prognostic factors. Results We included 247 patients with a median (interquartile range [IQR]) age at onset of 17 years (13–22) and a median follow‐up duration of 10 years (IQR = 5–20). Drug resistance at the last visit was observed in 40 (16.3%) patients, whereas the median latency to achieve 2‐year remission was 24 months (IQR = 24–46.5) with a median number of 1 (IQR = 1–2) ASM. During the long‐term follow‐up (i.e., 202 patients followed ≥5‐years after the first ASM trial), 69 (34.3%) patients displayed an early remission pattern and 36 (17.9%) patients displayed a late remission pattern, whereas 16 (8%) and 73 (36.3%) individuals had no‐remission and relapsing–remitting patterns, respectively. Catamenial seizures and morning predominance of generalized tonic–clonic seizures (GTCS) independently predicted drug resistance at the last visit according to multivariable logistic regression. Treatment withdrawal was attempted in 63 (25.5%) patients, with 59 (93.7%) of them having at least a 12‐month follow‐up after ASM discontinuation. At the last visit, 49 (83%) of those patients had experienced GTCS recurrence. A longer duration of seizure freedom was the only factor predicting a higher chance of successful ASM withdrawal according to multivariable Cox regression. Significance GTCA could be considered a relatively easily manageable IGE syndrome, with a low rate of drug resistance and a high prevalence of early response to treatment. Nevertheless, a considerable proportion of patients experience relapsing patterns of seizure control, highlighting the need for appropriate counseling and lifestyle recommendations.
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Collaborators (16)
Christoph P. Beier
-
Elena Merli
IRCCS Istituto Delle Scienze Neurologiche di Bologna
Christian Rummel
-
Antonio Gambardella
Professor of Neurology
Università degli Studi Mediterranea di Reggio Calabria
Andre Altmann
University College London
Elisa Bianchi
Mario Negri Institute for pharmacological research
Magdalena Kowalczyk
University of Melbourne
Eugenio Abela
Head
Psychiatrische Dienste Aargau AG
Enrico Iaccino
-
Rebekah V Harris
University of Melbourne
Maria Eugenia Caligiuri
-
Ilaria Sammarra
Magna Graecia University
Gloria Bertoli
Istituto di Biochimica e Biologia Cellulare, Consiglio Nazionale delle Ricerche
Ingrid Scheffer
University of Melbourne
Piero Perucca
-
Saul Mullen
University of Melbourne
Make your next move.
Prepare your application
Review drafts before you send them.